Lymph Node Biopsy

PROCEDURE14 trials

Sponsors

National Cancer Institute (NCI), Fred Hutchinson Cancer Center, University of California, San Francisco, Roswell Park Cancer Institute, Duke University

Conditions

AIDS-Related Anal CarcinomaAnal Margin Squamous Cell CarcinomaAnal Non-Keratinizing Squamous Cell CarcinomaAnal Squamous Cell CarcinomaB-cell Chronic Lymphocytic LeukemiaCervical AdenocarcinomaCervical Adenosquamous Cell CarcinomaCervical Small Cell Carcinoma

Early Phase 1

Ultrasound-Guided Photoacoustic Imaging for the Detection of Metastases in Inguinal Lymph Nodes

CompletedNCT04185337

M.D. Anderson Cancer CenterMalignant Neoplasm

Start: 2021-01-26End: 2025-02-25Updated: 2025-02-27

Phase 1

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

CompletedNCT00416455

National Cancer Institute (NCI)Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma +11

Start: 2007-09-30End: 2016-07-16Updated: 2019-07-23

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

CompletedNCT00621452

Fred Hutchinson Cancer CenterB-cell Chronic Lymphocytic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma +8

Start: 2007-08-31Target: 12Updated: 2014-08-06

Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer

CompletedNCT02036918

Duke UniversityProstate Cancer

Start: 2014-03-31End: 2019-02-06Updated: 2020-03-31

Phase 2

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

CompletedNCT02689427

M.D. Anderson Cancer CenterInvasive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7 +9

Start: 2016-09-22End: 2023-11-15Updated: 2024-09-19

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Active, not recruitingNCT04929028

National Cancer Institute (NCI)AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma +7

Start: 2022-08-09End: 2031-09-15Target: 40Updated: 2026-04-03

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

RecruitingNCT05873712

Aseel AlsouqiRecurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Non-Hodgkin Lymphoma +5

Start: 2023-07-28End: 2026-12-31Target: 24Updated: 2026-03-03

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

RecruitingNCT06381154

Mayo ClinicLocally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 +3

Start: 2024-12-06End: 2029-12-06Target: 25Updated: 2026-01-30

Phase 3

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Not yet recruitingNCT07466316

Children's Oncology GroupRhabdomyosarcoma

Start: 2026-06-22End: 2031-03-31Target: 342Updated: 2026-03-12

Unknown Phase

The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

RecruitingNCT01202305

University of California, San FranciscoHIV

Start: 2011-04-30End: 2030-04-30Target: 50Updated: 2025-04-06

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

TerminatedNCT01649791

Roswell Park Cancer InstituteB-cell Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia +2

Start: 2010-01-31End: 2014-10-31Updated: 2016-06-30

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

Active, not recruitingNCT02276443

M.D. Anderson Cancer CenterInvasive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7 +9

Start: 2015-11-09End: 2026-11-30Updated: 2025-08-01

HIV Persistence in Lymph Node and Peripheral Blood

CompletedNCT03426189

University of MelbourneHIV-1-infection

Start: 2017-01-02End: 2018-10-17Updated: 2021-06-23

Sarcoidosis Immunotsuppressive Therapy and Lymphoma Development

CompletedNCT07343401

Alexandria UniversitySarcoidosis Lung

Start: 2025-08-01End: 2026-01-01Updated: 2026-01-15

Related Papers

Abstract PD7-03: Circulating Immune Correlates of Pathological Response to Neoadjuvant Pembrolizumab plus Chemotherapy in High-Risk, Early-Stage Triple-Negative Breast Cancer

Clinical Cancer Research2026-02-17

Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer.

2025-11-20

Data from An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy

2025-11-03

A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation

Blood2025-11-03

An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant Chemotherapy.

2025-11-01

Abstract PS1-07: Al-Derived Tumor-Infiltrating Lymphocytes Enhance the Model with Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Predicting Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial

Clinical Cancer Research2025-06-13

Abstract P2-02-25: Predicting the response of triple negative breast cancer to neoadjuvant systemic therapy via biology-based modeling and habitat analysis

Clinical Cancer Research2025-06-13

Early on-treatment (on-Rx) tumor volume reduction (TVR) to predict response to the KEYNOTE-522 (KN-522) regimen in early stage triple negative breast cancer (TNBC).

Journal of Clinical Oncology2025-05-28

Abstract 6245: Predicting and optimizing the response of breast cancer patients to neoadjuvant therapy using a multiscale computational model

Cancer Research2025-04-211 citations

MRI-based digital twins to improve treatment response of breast cancer by optimizing neoadjuvant chemotherapy regimens.

2025-04-074 citations

Deep Learning Models Based on Pretreatment MRI and Clinicopathological Data to Predict Responses to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer

Cancers2025-03-136 citations

Combining Biology-based and MRI Data-driven Modeling to Predict Response to Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

2025-01-016 citations

Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer.

2024-11-182 citations

Abstract PO5-07-03: Integrating mechanism-based and data-driven modeling to predict the response of triple negative breast cancer to therapy

Cancer Research2024-05-02

Abstract PS05-07: Early prediction of response to Neoadjuvant Immunotherapy in Triple Negative Breast Cancer (TNBC) with DCE-MRI

Cancer Research2024-05-02

Abstract 6620: PDX models of TNBC established from pre- and post-therapy tumors identify vulnerabilities of resistant disease

Cancer Research2024-03-221 citations

Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes

JCO Precision Oncology2024-03-013 citations

Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer

Frontiers in Oncology2023-10-248 citations

A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer

Radiology Imaging Cancer2023-07-0127 citations

Abstract 845: Developing MRI-based digital-twins via mathematical modeling and deep learning to predict the response of triple-negative breast cancer to neoadjuvant therapy

Cancer Research2023-04-04

40 more papers not shown